Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST
Allschwil, Switzerland - June 2
, 2021
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y
12 receptor antagonist, in suspected acute myocardial infarction (AMI).
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, each year more than 80
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute .
Idorsia Pharmaceuticals LtdJune 28, 2021 GMT
Ad hoc announcement pursuant to Art. 53 LR
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST
Allschwil, Switzerland – June 28, 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversi
and Chair of the Steering Committee
for SOS-AMI, commented: P2Y
12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class.
To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the potential to s